Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

Jingjing Li, Xuanfu Xu Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, People’s Republic of ChinaCorrespondence: Xuanfu Xu, Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, People’s Republic of China, Tel +86-021-25066666, Email shuanfusky@163.comAbstra...

Full description

Bibliographic Details
Main Authors:	Li J, Xu X
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-04-01
Series:	International Journal of General Medicine
Subjects:	immune checkpoint inhibitors colorectal cancer pd-1/pd-l1 combination therapy dna mismatch repair
Online Access:	https://www.dovepress.com/immune-checkpoint-inhibitor-based-combination-therapy-for-colorectal-c-peer-reviewed-fulltext-article-IJGM

Similar Items

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
by: François Ghiringhelli, et al.
Published: (2019-08-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

An overview of immune checkpoint inhibitor toxicities in bladder cancer
by: Avenie Mavadia, et al.
Published: (2024-12-01)

Immune Checkpoint Inhibitors in Cancer Therapy
by: Yavar Shiravand, et al.
Published: (2022-04-01)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
by: Yuxiao Song, et al.
Published: (2020-08-01)

Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis
by: Dandan Song, et al.
Published: (2024-11-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
by: Ya Xu, et al.
Published: (2020-10-01)

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
by: Julie M. Collins, et al.
Published: (2018-08-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Research progress of immune checkpoint inhibitors in the treatment of metastatic colorectal cancer
by: TU Juanjuan, et al.
Published: (2023-02-01)

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching
by: Zeyang Wang, et al.
Published: (2024-11-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
by: Alberto Bongiovanni, et al.
Published: (2021-05-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
by: Ji Won Han, et al.
Published: (2021-09-01)

Tumour-immune dynamics with an immune checkpoint inhibitor
by: Elpiniki Nikolopoulou, et al.
Published: (2018-06-01)

Recommendation of Diagnosis and Management for the Infections Related to Immune Checkpoint Inhibitors
by: Minya LU, et al.
Published: (2019-10-01)

Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
by: Minya Lu, et al.
Published: (2020-03-01)

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
by: Zhengyang Yang, et al.
Published: (2022-09-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
by: Adel Naimi, et al.
Published: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
by: Zhanjun Guo, et al.
Published: (2022-03-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
by: Deniz Can Guven, et al.
Published: (2022-10-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
by: Jiaxin Zhou, et al.
Published: (2022-07-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
by: Juwon Lee, et al.
Published: (2021-07-01)

Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review
by: Yu CW, et al.
Published: (2020-11-01)

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
by: Charissa A. C. Jessurun, et al.
Published: (2017-09-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
by: Ahmed M. Basudan
Published: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
by: Gabriel Surdacki, et al.
Published: (2019-03-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

Enhancing cancer care with improved checkpoint inhibitors
by: Vickram A S, et al.
Published: (2024-10-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
by: Amjad Zafar, et al.
Published: (2024-11-01)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
by: Katarina Hradska, et al.
Published: (2021-08-01)

Immune checkpoint inhibitors and prostate cancer: a new frontier?
by: Alessandra Modena, et al.
Published: (2016-04-01)

Comprehensive overview of biomarkers to predict response to immune checkpoint therapy in lung cancer
by: Kriti Jain, et al.
Published: (2023-01-01)

Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors
by: Qi Zhang, et al.
Published: (2024-12-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
by: Gwenyth J. Joseph, et al.
Published: (2023-12-01)

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)
by: Caicun ZHOU, et al.
Published: (2020-02-01)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
by: Yue Zhang, et al.
Published: (2022-04-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
by: Ruby Dhar, et al.
Published: (2023-04-01)